Subject: More Big News for ICOR

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
More Big News for ICOR
Hot Stock to WatchHot Stock to Watch

Company: InterCore Energy Inc. (OTCQB: ICOR)

End of Day:

Price: 4.31

Change (%): - 0.44 (9.26)

Volume: 1,616
ICOR Chart

InterCore, Inc. Announces a Pilot Contract With PT Trans Continent in Indonesia

DELRAY BEACH, FL-(Marketwired - Mar 17, 2015) - InterCore, Inc. (OTCQB: ICOR) is pleased to announce that its Driver Alertness Detection System (DADS™) will be deployed in a trial installation with PT Trans Continent, Indonesia.

PT Trans Continent is the leading Supply Chain operator for Sodium Cyanide used in the Gold Mining Industries in the Republic of Indonesia. DADS will be installed for a three-month trial in PT Trans Continent vehicles that are part of the more than 2,000 trucks in this segment of the Indonesian market.

“Fatigue is a major killer in the trucking industry in Indonesia. Being able to accurately monitor drivers in real time for their safety, and the safety of the goods they haul, is on the top of our agenda,” said George Chin, Technical Advisor and Consultant, PT Trans Continent. “A system like DADS - Driver Alertness Detection System - is part of our contribution to the communities that we work within. Our clients will know they can trust us with their dangerous goods, and the families of our drivers can feel secure when they entrust their loved ones to us.”

Continue Reading

Top PerformerYesterday's Top Performer

Terra Tech Corp (OTCQB: TRTC)

End of Day:

Price: 0.184

Change (%): + 0.0085 (4.84)

Volume: 801,375
TRTC Chart

About Terra Tech

Terra Tech Corp. (TRTC) through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. Our complete product line is available at specialty retailers throughout the United States, and via our website. Through its wholly-owned subsidiary Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as Shoprite, Food Emporium and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, and Pennsylvania. MediFarm LLC is focused on medical cannabis businesses throughout Nevada. IVXX LLC is a wholly owned subsidiary that produces medical cannabis extracted products sold to permitted medical cannabis dispensaries throughout California.

Company Information Sheet

Other Small Cap News

Company: Neurotrope, Inc. (OTCQB: NTRP)

Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease

Study reveals preliminary evidence of target engagement of PKCe which the company believes is critical to improving cognitive function

NEWARK, N.J., March 17, 2015 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced secondary and exploratory endpoint results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer's disease (AD). Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCe). The Company is approaching the treatment of Alzheimer's disease through the activation of PKCe. In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration.

Final analysis of this Phase 2a safety study, in nine Alzheimer's patients with mild dementia as measured by MMSE-2 scores, confirms the previously announced result. The study has met its primary endpoint demonstrating preliminary safety and tolerability of bryostatin. No safety signals have been identified.

Continue Reading

Company: United Treatment Centers, Inc. (Pink Sheets: UTRM)

United Treatment Centers, Inc. Appoints New Management Team at PotNetwork Inc.

PotNetwork Reveals Corporate Strategy

FT LAUDERDALE, FL--(Marketwired - Mar 17, 2015) - United Treatment Centers, Inc. (OTC PINK: UTRM) is pleased to announce that the Company has appointed three new key executives at PotNetwork Incorporated; a wholly owned subsidiary of United Treatment Centers Inc. Richard Volpe has been appointed as the Company's Chief Executive Officer, Keith Levinson as President, and Lane Tyler Radbill, as the Vice President of Content Development. "I am pleased with the accomplishments that we have achieved in such a short time, I look forward to the team we have appointed executing their business plan they have set forth; in addition we are pleased to report that we are continuing our relationship with Neovix Inc., our streaming video provider." said Steven Buckner CEO of United Treatment Centers Inc.

Now headquartered in Denver Colorado, the epicenter of the legal Marijuana trade, under the direction of Mr. Levinson, PotNetwork is rolling out a comprehensive new strategy, complete with new video segments, and exclusive content designed to entertain, educate, and empower the cannabis enthusiast.

Continue Reading

Company: Regen BioPharma Inc. (OTCBB/QB: RGBP)

Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application

Company Believes GLP Safety Study Is the Last Hurdle for HemaXellerate IND

SAN DIEGO, CA--(Marketwired - Mar 17, 2015) - Regen BioPharma Inc. (OTCBB/QB: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.

Dr. Thomas Ichim stated, "The FDA has reviewed our protocols for the GLP Safety Study. They made several comments which have been incorporated into our protocols. The next step is for Regen to commence this study. Once completed, the results will be presented to the FDA. We believe that this process represents the last hurdle for Regen's HemaXellerate IND to clear before we are allowed to move into clinical trials."

Continue Reading

Company: Peak Pharmaceuticals, Inc. (OTCQB: PKPH)

Canna-Pet™ Announces Availability on Amazon and April Launch of New MaxCBD Canna-Biscuits

BOULDER, CO--(Marketwired - Mar 17, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (the "Company"), and Canna-Pet, a leading innovator of over-the-counter cannabinoid products for animals, are pleased to announce the launch of the Canna-Pet™ product line on Amazon Services, LLC ("Amazon") and the upcoming release of a newly formulated dog treat to extend the popular Canna-Biscuit product lineup.

The Company's initial launch of Canna-Pet™ capsules on Amazon will shortly be followed by the availability of Canna-Biscuit dog treats in order to offer the Company's full product lineup of CBD supplements for cats and dogs. All products are available as part of Amazon Prime, offering significant membership advantages and launching an all new and exciting sales channel for the Company and Canna-Pet™ customers alike.

Continue Reading

Market News


Investors slash US exposure on rate hike fears

Global fund managers have trimmed their exposure to U.S. stocks to the lowest levels since 2008 in anticipation of a U.S. Federal Reserve rate rise, with increasing numbers expecting the central bank to move in the second quarter of this year.

In March, a net 19 percent of global asset allocators polled in Bank of America Merrill Lynch's regular fund manager survey were underweight U.S. equities. This marked a swing from net 6 percent overweight in February and is the biggest underweight stance on U.S. stocks since January 2008.

In addition, the proportion of investors saying U.S. equities were overvalued surged to 23 percent, the highest level since May 2000.

Continue Reading

By Sinead Carew:

Wall St opens lower ahead of Fed meeting

(Reuters) - U.S. stocks pulled back on Tuesday from a rally in the previous session ahead of a Federal Reserve meeting that investors hope will bring insight on the timing of an interest rate hike.

The Federal Open Market Committee is due to start a two-day meeting on Tuesday and is expected to put out its statement and projections on Wednesday afternoon.

Most economists expect the Fed to remove a pledge to be "patient" about raising interest rates from its statement, giving it flexibility on when to kick off its first rate hike since 2006.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks